Niagen Bioscience (NAGE) Share-based Compensation (2011 - 2026)

Niagen Bioscience (NAGE) has 16 years of Share-based Compensation data on file, last reported at $1.7 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.7 million, up 59.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.7 million (up 79.02% YoY), and the FY2025 annual result was $6.1 million, up 65.95% from the prior year.
• Share-based Compensation retreated to $1.7 million in Q1 2026 per NAGE's latest filing, from $1.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $1.9 million in Q1 2022 and troughed at $735000.0 in Q3 2024.
• A 5-year average of $1.3 million and a median of $1.3 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation slumped 34.2% in 2024, then soared 138.91% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2022, then fell by 21.79% to $1.0 million in 2023, then decreased by 27.48% to $752000.0 in 2024, then surged by 132.45% to $1.7 million in 2025, then retreated by 1.83% to $1.7 million in 2026.
• Business Quant data shows NAGE's Share-based Compensation at $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.